417 related articles for article (PubMed ID: 32920498)
1. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
4. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
[TBL] [Abstract][Full Text] [Related]
9. Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Auguste P; Colquitt J; Connock M; Loveman E; Court R; Ciccarelli O; Counsell C; Armoiry X
Pharmacoeconomics; 2020 Jun; 38(6):527-536. PubMed ID: 32048205
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
12. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
14. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
[TBL] [Abstract][Full Text] [Related]
15. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
17. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.
Patel A; Sul J; Gordon ML; Steinklein J; Sanguinetti S; Pramanik B; Purohit D; Haroutunian V; Williamson A; Koralnik I; Harel A
JAMA Neurol; 2021 Jun; 78(6):736-740. PubMed ID: 33724354
[TBL] [Abstract][Full Text] [Related]
18. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
Hauser SL; Kappos L; Montalban X; Craveiro L; Chognot C; Hughes R; Koendgen H; Pasquarelli N; Pradhan A; Prajapati K; Wolinsky JS
Neurology; 2021 Oct; 97(16):e1546-e1559. PubMed ID: 34475123
[TBL] [Abstract][Full Text] [Related]
19. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort.
Tallantyre EC; Castle D; Karamura P; Brice TAW; Joseph F; Harding KE; Robertson NP
Mult Scler Relat Disord; 2020 Jul; 42():102056. PubMed ID: 32353753
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab: A Review in Multiple Sclerosis.
Syed YY
CNS Drugs; 2018 Sep; 32(9):883-890. PubMed ID: 30171504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
